HeartSciences extends loan maturity to 2026, raises $6.7M in Reg A, exchanges $2.06M debt for equity

HeartSciences Inc.

Loan maturity extended to Sept 30, 2026; accrued interest payment structure amended.
Raised $6.7M gross from Reg A offering of 1,912,383 Units as of Oct 1, 2025.
Converted 1,331,044 Series D Preferred shares into common stock under Reg A.
Exchanged $2.06M principal + $45K accrued interest for 597,578 common shares.
Common shares outstanding total 3,069,635 as of Oct 1, 2025.

item 1.01 item 2.03 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

HeartSciences Inc. amended loan of $500,000 with Front Range Ventures LLC at 12% per annum maturing September 30, 2026.

Instrument: loan
Principal: $500,000
Counterparty: Front Range Ventures LLC
Rate: 12% per annum
Maturity: September 30, 2026
Event: amendment

Exact text from the filing

Loan Agreement, the No. 1 Amendment, the No. 2 Amendment, the No. 3 Amendment, the No. 4 Amendment and the No. 5 Amendment, the “Loan Agreement”), for the Company to borrow $500,000 from Front Range Ventures LLC (“FRV”) as evidenced by a secured, non-convertible promissory note, dated April 24, 2020, as amended by the Amended and Restated Secured Promissory

View on SEC.gov

306 debt financings filed in the last 30 days. Browse all debt financings →

HeartSciences Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-227023

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.